Bio-Rad Laboratories, Inc.
Description
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
About
CEO
Mr. Norman D. Schwartz
Employees
7,700
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Devices
MIC code
XNYS
Address
1000 Alfred Nobel Drive, Hercules, CA 94547, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 28, 2025 | — | — | — | — |
| Jul 30, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Feb 13, 2025 | 2.86 | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 5 | — | 6 |
| Average estimate | — | 2.64 | — | 11.33 |
| Low estimate | — | 2.28 | — | 10.13 |
| High estimate | — | 3.00 | — | 11.77 |
| Last year EPS | — | 2.29 | — | 10.06 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-6.900%
Next qtr. (Mar 2025)
15.230%
Current year
-14.570%
Next year (Dec 2025)
12.630%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 2.67B | 2.80B | 2.92B | 2.55B | 2.31B |
| Cost of revenue | 1.24B | 1.23B | 1.28B | 1.11B | 1.05B |
| Gross profit | 1.43B | 1.57B | 1.64B | 1.44B | 1.26B |
| Operating expense | |||||
| Research & development | 247.43M | 256.89M | 260.64M | 217.76M | 202.71M |
| Selling general and admin | 841.72M | 827.83M | 877.12M | 798.80M | 824.63M |
| Other operating expenses | — | 7.50M | — | — | — |
| Operating income | 337.80M | 475.12M | 500.34M | 421.33M | 229.66M |
| Non operating interest income | |||||
| Income | 100.90M | 58.00M | 18.90M | 18.20M | 30.50M |
| Expense | 49.44M | 38.11M | 1.55M | 21.86M | 23.42M |
| Other income expense | -1.24B | -5.20B | 4.93B | 4.50B | 2.02B |
| Pretax income | -850.10M | -4.70B | 5.45B | 4.92B | 2.26B |
| Tax provision | -212.78M | -1.08B | 1.19B | 1.10B | 502.41M |
| Net income | -637.32M | -3.63B | 4.25B | 3.81B | 1.76B |
| Basic EPS | -21.82 | -121.79 | 142.33 | 127.86 | 58.93 |
| Diluted EPS | -21.82 | -121.79 | 140.56 | 126.20 | 58.27 |
| Basic average shares | 29.21M | 29.79M | 29.83M | 29.77M | 29.84M |
| Diluted average shares | 29.21M | 29.79M | 29.83M | 29.77M | 29.84M |
| EBITDA | 586.94M | 672.69M | 657.51M | 576.31M | 394.26M |
| Net income from continuing op. | -637.30M | -3.63B | 4.25B | 3.81B | 1.76B |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 12.30B | 13.50B | 17.80B | 12.97B | 8.01B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 403.82M | 434.22M | 470.78M | 662.21M | 660.67M |
| Other short term investments | 1.20B | 1.36B | 399.14M | 328.91M | 453.97M |
| Accounts receivable | 489.02M | 494.65M | 423.54M | 419.42M | 392.67M |
| Other receivables | — | — | — | — | — |
| Inventory | 780.52M | 719.32M | 572.24M | 622.25M | 554.01M |
| Prepaid assets | 140.04M | 124.18M | 109.14M | 90.62M | 102.33M |
| Restricted cash | 5.56M | 5.56M | 5.56M | 5.56M | 5.56M |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 26.05M | 23.60M | 10.09M | 10.86M | 10.94M |
| Non current assets | |||||
| Properties | 1.34B | 1.27B | 1.30B | 1.27B | 1.22B |
| Land and improvements | 28.40M | 27.80M | 27.94M | 25.74M | 25.22M |
| Machinery furniture equipment | — | — | — | 1.06B | 1.02B |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -1.07B | -1.01B | -1.00B | -961.39M | -882.83M |
| Goodwill | 1.15B | 1.15B | 948.50M | 783.30M | 673.70M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 320.50M | 332.10M | 253.90M | 199.50M | 145.50M |
| Investments and advances | 7.70B | 8.83B | 14.39B | 9.56B | 4.64B |
| Other non current assets | 94.85M | 94.60M | 104.19M | 86.72M | 79.64M |
| Total liabilities | 3.56B | 3.89B | 4.11B | 3.09B | 2.25B |
| Current liabilities | |||||
| Accounts payable | 144.63M | 135.04M | 141.94M | 139.45M | 107.01M |
| Accrued expenses | 139.93M | 194.79M | 276.99M | 222.88M | 180.08M |
| Short term debt | 40.87M | 36.80M | 36.92M | 38.31M | 461.57M |
| Deferred revenue | — | 52.21M | 50.85M | 42.47M | 33.74M |
| Tax payable | 35.76M | 32.43M | 46.30M | 57.34M | 36.29M |
| Pensions | — | — | — | — | — |
| Other current liabilities | 161.62M | 169.65M | 127.94M | 131.10M | 86.81M |
| Non current liabilities | |||||
| Long term debt | 1.36B | 1.35B | 186.45M | 187.43M | 189.62M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 1.48B | 1.77B | 3.06B | 2.08B | 997.79M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 195.07M | 195.93M | 182.19M | 196.93M | 160.90M |
| Shareholders equity | |||||
| Common stock | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 |
| Retained earnings | 9.26B | 9.90B | 13.53B | 9.27B | 5.47B |
| Other shareholders equity | -336.04M | -466.82M | -175.55M | 282.46M | -87.35M |
| Total shareholders equity | 8.74B | 9.62B | 13.69B | 9.88B | 5.76B |
| Additional paid in capital | 449.08M | 447.45M | 441.73M | 429.38M | 410.02M |
| Treasury stock | 632.54M | 263.59M | 106.29M | 99.91M | 38.40M |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||||||||
| Net Income | -637.30M | -3.63B | 4.25B | 3.81B | 1.76B | 365.60M | 122.20M | 26.00M | 109.20M | 88.80M | 77.80M | 165.50M | 178.80M | 186.90M | 149.17M | 98.26M | 92.99M | 103.26M | 81.60M | 68.20M | 76.20M | 68.53M | 44.20M | 31.81M | 11.72M | 24.30M | 16.40M | 27.40M | 25.20M | 15.60M | 2.80M | 15.60M | 8.20M | 10.70M | 10.10M |
| Depreciation | 145.90M | 137.30M | 137.60M | 138.60M | 134.20M | 138.10M | 148.70M | 142.90M | 131.80M | 149.90M | 147.20M | 130.40M | 121.00M | 108.90M | 101.70M | 97.10M | 67.30M | 55.40M | 61.00M | 55.50M | 42.00M | 38.00M | 41.30M | 43.31M | 27.50M | 20.98M | 19.50M | 17.90M | 16.70M | 16.80M | 16.60M | 13.90M | 12.10M | 10.30M | 7.90M |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -5.90M | 1.20M | -15.00M | 2.50M | -8.00M | 12.70M | -1.70M | 3.38M | -16.90M | -5.30M | -1.30M | -4.90M | -1.30M | 3.90M | 3.40M | -2.80M | 600,000 | -1.70M | -300,000 |
| Stock-Based Compensation | 61.30M | 60.90M | 51.20M | 41.60M | 35.60M | 27.80M | 23.40M | 19.70M | 17.00M | 14.90M | 13.70M | 13.20M | 10.70M | 10.20M | 9.10M | 7.30M | — | 5.40M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | -11.96M | 22.15M | 8.66M | 4.57M | -1.00M | -1.31M | -12.96M | 5.37M | -1.29M | 2.61M | -5.76M | -16.12M | 35,000 | 4.91M | 909,000 | -1.19M | 21.19M | -36.25M | 16.78M | 13.39M | 22.34M | 6.84M | 26.40M | -1.59M | 1.38M | -277,000 | -900,000 | -1.10M | -100,000 | 800,000 | — | -100,000 | -200,000 | 100,000 | -1.20M |
| Accounts Receivable | 11.40M | -87.40M | -20.40M | -15.00M | 1.60M | 59.70M | -64.10M | 12.50M | -39.00M | 11.10M | -24.20M | 4.40M | -20.10M | -37.00M | 4.30M | 11.10M | 9.00M | -25.50M | -7.70M | -4.40M | 10.00M | -700,000 | -22.60M | -329,000 | -16.10M | -5.70M | -6.20M | -6.70M | -9.30M | -2.10M | -2.30M | -7.60M | -5.40M | -6.50M | -6.50M |
| Accounts Payable | -51.80M | -94.20M | 69.90M | 124.70M | 10.60M | -45.60M | 7.80M | 30.10M | 28.60M | -9.90M | 33.20M | 19.00M | -6.60M | 9.10M | — | -3.60M | — | 17.30M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -371.10M | -1.43B | 1.12B | 940.20M | 547.90M | 83.80M | -125.00M | -92.40M | -68.50M | -3.90M | -33.20M | -17.60M | -25.00M | -31.70M | 47.60M | -52.50M | -8.50M | -39.60M | -29.20M | -4.80M | -28.00M | 1.83M | 800,000 | -44.45M | 14.50M | 5.40M | -20.10M | 5.70M | 1.80M | 2.30M | 9.10M | -14.60M | -12.20M | -7.50M | -4.60M |
| Operating Cash Flow | -853.56M | -5.02B | 5.62B | 5.05B | 2.49B | 628.09M | 100.04M | 144.17M | 177.81M | 253.51M | 208.74M | 298.78M | 258.84M | 251.31M | 312.77M | 156.47M | 176.08M | 81.21M | 107.48M | 130.39M | 114.54M | 127.19M | 88.40M | 32.14M | 22.10M | 39.40M | 7.40M | 38.30M | 33.00M | 37.30M | 29.60M | 4.40M | 3.10M | 5.40M | 5.40M |
| Investing Activities | |||||||||||||||||||||||||||||||||||
| Capital Expenditures | -156.47M | -112.62M | -133.69M | -108.49M | -98.40M | 4.32M | 86,000 | 398,000 | 79,000 | 225,000 | 1.21M | 6.33M | 234,000 | 1.19M | — | — | -62.67M | -52.99M | -36.06M | -40.72M | -69.00M | -42.22M | -43.23M | 2.71M | -230.10M | -21.20M | -54.80M | -15.20M | -12.30M | -9.80M | -14.50M | -19.50M | -31.00M | -13.40M | -13.40M |
| Net Intangibles | — | -1.38M | — | 3.41M | 8.82M | -3,000 | -3.80M | -135,000 | -1.37M | -15.48M | -700,000 | -1.78M | -436,000 | -4.08M | -9.57M | -4.00M | -2.08M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | 2.50M | -99.39M | -125.52M | -84.42M | -79.39M | 6.96M | — | — | -4.36M | -44.63M | -72.05M | -39.44M | -158.54M | -89.31M | -35.99M | -53.01M | -387.67M | -46.07M | -4.34M | -58.98M | -16.38M | -8.57M | -4.65M | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -689.04M | -2.06B | -851.63M | -248.46M | -371.45M | -371.02M | -359.30M | -292.24M | -294.50M | -205.75M | -386.71M | -680.97M | -509.31M | -240.29M | -147.55M | -77.80M | -270.17M | -334.05M | -873.82M | -2.26B | -600.00M | -1.89M | -567,000 | -326,000 | -2.20M | -19.10M | -8.40M | -2.70M | -3.10M | -1.40M | -200,000 | -3.30M | -900,000 | -100,000 | — |
| Sale of Investments | 863.22M | 1.07B | 766.90M | 368.06M | 331.53M | 302.59M | 299.77M | 219.88M | 249.49M | 196.12M | 565.83M | 458.35M | 384.61M | 210.85M | 86.47M | 78.91M | 470.20M | 178.64M | 942.79M | 2.17B | 510.14M | 493,000 | 497,000 | 795,000 | 6.60M | 16.40M | 3.40M | 3.00M | 3.00M | 1.30M | 5.10M | 12.00M | 5.10M | 200,000 | 200,000 |
| Investing Cash Flow | 20.21M | -1.21B | -797.38M | -73.31M | -217.71M | -57.15M | -60.45M | -72.31M | -53.50M | -54.03M | 108.28M | -255.74M | -280.09M | -123.98M | -99.59M | -57.30M | -254.43M | -207.75M | -6.17M | -186.32M | -190.24M | -54.46M | -47.54M | 9.30M | -223.30M | -25.30M | -55.90M | -14.80M | -13.90M | -13.10M | -8.80M | -12.10M | -26.60M | -17.60M | -16.80M |
| Financing Activities | |||||||||||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | 1.19B | — | — | — | — | — | 37,000 | — | — | 48,000 | — | — | 424.63M | 294.75M | 1.60M | 24,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -467,000 | -510,000 | -3.02M | -426.94M | -643,000 | -2.96M | -352,000 | -303,000 | -282,000 | -1.81M | -300.23M | -811,000 | -230.74M | -207.54M | -9.13M | -13.23M | -22.05M | -1.15M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -14.94M | -14.02M | -23.04M | -16.30M | -11.06M | -10.94M | -10.99M | -1.99M | 627,000 | -1.55M | -22.75M | 2.89M | 2.93M | -1.08M | -1.98M | 5.05M | 2.99M | 1.39M | -331,000 | -2.88M | — | — | — | -4.50M | -4.90M | — | — | -100,000 | — | — | — | -100,000 | — | 100,000 | — |
| Financing Cash Flow | -444.13M | 956.02M | -76.06M | -543.24M | -39.70M | -62.81M | -6.97M | 9.02M | 8.58M | 11.69M | -311.70M | 12.59M | -217.46M | 227.92M | 291.63M | 4.69M | -11.78M | 9.50M | 8.58M | 4.59M | 5.31M | 5.33M | 4.68M | -2.49M | -5.50M | -2.60M | -3.10M | -500,000 | 1.10M | 800,000 | 800,000 | 800,000 | 900,000 | 1.20M | 800,000 |
| Other Cash Details | |||||||||||||||||||||||||||||||||||
| End Cash Position | 404.37M | 434.54M | 471.13M | 667.12M | 662.65M | 434.16M | 384.98M | 457.17M | 457.55M | 413.25M | 331.55M | 463.39M | 574.23M | 906.55M | 649.94M | 204.52M | 161.76M | 223.61M | 296.72M | 195.73M | 65.40M | 27.73M | 47.13M | 13.95M | 17.10M | 10.10M | 10.80M | — | — | — | — | — | — | — | — |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 218.26M | 80.29M | 535.72M | 476.41M | 359.37M | 155.67M | -10.99M | 74.50M | 72.84M | 136.83M | 61.78M | 121.83M | 159.41M | 133.38M | 248.71M | 102.56M | 128.91M | 65.24M | 72.23M | 62.60M | 58.64M | 63.53M | 56.27M | -7.16M | -185.10M | 6.10M | -33.70M | 18.00M | 25.90M | 38.50M | 8.00M | -16.40M | -26.90M | -1.30M | -3.60M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| VanEck ETF Trust-VanEck Morningstar Wide Moat ETF | Nov 30, 2024 | 1,237,113 | 428.08M | 5.40% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 614,364 | 212.59M | 2.68% |
| iShares Core S&P Midcap ETF | Nov 30, 2024 | 614,879 | 212.77M | 2.68% |
| First Eagle Global Fund | Oct 31, 2024 | 525,458 | 181.82M | 2.29% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 484,981 | 167.82M | 2.12% |
| Vanguard Small Cap Value Index Fund | Sep 30, 2024 | 328,307 | 113.60M | 1.43% |
| Parnassus Value Equity Fund | Sep 30, 2024 | 310,732 | 107.52M | 1.36% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 281,667 | 97.47M | 1.23% |
| Longleaf Partners Fund | Sep 30, 2024 | 196,969 | 68.16M | 0.86% |
| DFA U.S. Small Cap Value Series | Oct 31, 2024 | 183,867 | 63.62M | 0.80% |
Article
Oncocyte Prices $29.1 Million Equity Offering
IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE Offering”).
Feb 10, 2025
Article
Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Feb 6, 2025
Article
Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?
Here is how Bio-Rad Laboratories (BIO) and Certara, Inc. (CERT) have performed compared to their sector so far this year.
Feb 4, 2025
